These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19005745)

  • 21. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
    Oemrawsingh RM; Akkerhuis KM; Van Vark LC; Redekop WK; Rudez G; Remme WJ; Bertrand ME; Fox KM; Ferrari R; Danser AH; de Maat M; Simoons ML; Brugts JJ; Boersma E;
    J Am Heart Assoc; 2016 Mar; 5(3):e002688. PubMed ID: 27021566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?
    Shah AD; Arora RR
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):281-3. PubMed ID: 16382264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
    Mackay JA
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
    Simoons ML; Vos J; de Feyter PJ; Bots ML; Remme WJ; Grobbee DE; Kluft C; de Maat MP; Fox KM; Deckers JW
    Eur Heart J; 1998 Sep; 19 Suppl J():J56-60. PubMed ID: 9796842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives.
    Tropeano AI; Boutouyrie P; Pannier B; Joannides R; Balkestein E; Katsahian S; Laloux B; Thuillez C; Struijker-Boudier H; Laurent S
    Hypertension; 2006 Jul; 48(1):80-6. PubMed ID: 16702490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
    Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
    Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perindopril for the treatment of hypertension.
    Ghiadoni L
    Expert Opin Pharmacother; 2011 Jul; 12(10):1633-42. PubMed ID: 21599567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
    Fox K; Ferrari R; Yusuf S; Borer JS
    Eur Heart J; 2006 Sep; 27(18):2154-7. PubMed ID: 16905555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
    Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
    van Gilst WH; Warnica JW; Baillot R; Johnstone D; Calciu CD; Block P; Myers MG; Chocron S; Rouleau JL;
    Am Heart J; 2006 Jun; 151(6):1240-6. PubMed ID: 16781228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE.
    Verma S; Leiter LA; Lonn EM; Strauss MH
    Eur Heart J; 2005 Jul; 26(14):1347-9. PubMed ID: 15872030
    [No Abstract]   [Full Text] [Related]  

  • 32. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
    Brugts JJ; Boersma E; Simoons ML
    Pharmacogenomics; 2010 Aug; 11(8):1115-26. PubMed ID: 20712529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Scientific value of the EUROPA Study: mechanisms of beneficial effect of perindopril in atherosclerosis].
    Karpov IuA
    Kardiologiia; 2005; 45(2):86-9. PubMed ID: 15798719
    [No Abstract]   [Full Text] [Related]  

  • 34. Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure.
    Krysiak R; Okopień B
    Pharmacol Rep; 2012; 64(6):1466-75. PubMed ID: 23406757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats.
    Naelten G; Liu KL; Chapuis B; Lo M
    Am J Hypertens; 2005 May; 18(5 Pt 1):699-706. PubMed ID: 15882554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats.
    Yamada K; Horita T; Takayama M; Takahashi S; Takaba K; Nagata Y; Suzuki N; Kanda T
    Brain Res; 2011 Nov; 1421():110-20. PubMed ID: 21981801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
    Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
    Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of angiotensin-converting enzyme inhibition on skeletal muscle oxidative function and exercise capacity in streptozotocin-induced diabetic rats.
    Rouyer O; Zoll J; Daussin F; Damgé C; Helms P; Talha S; Rasseneur L; Piquard F; Geny B
    Exp Physiol; 2007 Nov; 92(6):1047-56. PubMed ID: 17675412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.